jes-pa-mra-normotensive

Recommends mineralocorticoid receptor antagonists for all primary aldosteronism patients to prevent target organ damage, irrespective of blood pressure control or serum potassium levels. Triggered whe

SKILL.md

GitHub

Determine when to use MRAs in PA patients with controlled blood pressure and normal potassium

STEP 1 — Gather Information

Confirm PA diagnosis via positive screening (ARR ≥200, PAC ≥60 pg/mL) and a confirmatory test; document office/home BP (<130/80 mmHg), serum potassium (3.5‑5.0 mmol/L), current antihypertensives, baseline eGFR and urinalysis.

STEP 2 — Rule In / Rule Out

Is the patient diagnosed with primary aldosteronism?

  • No → Manage hypertension per usual guidelines; MRA not indicated for PA.
  • Yes → Proceed to step 3.

STEP 3 — Classify or Stratify

Assess for contraindications: serum K >5.0 mmol/L, eGFR <30 mL/min/1.73 m², pregnancy (unless spironolactone after first trimester with obstetric advice), or concomitant use of potassium‑sparing agents with eplerenone/esaxerenone.

  • Contraindication present → Avoid MRA; consider alternative antihypertensives or specialist referral.
  • No contraindication → Proceed to step 4.

STEP 4 — Decide

Initiate MRA: spironolactone 25‑50 mg daily, eplerenone 2.5‑5 mg daily, or esaxerenone 1.25‑2.5 mg daily. Re‑check serum potassium, creatinine, and BP at 4‑6 weeks; continue long‑term to prevent target organ damage.

Clinical Guardrails / Mimics / Pitfalls

Do not start MRA if K >5.0 mmol/L or eGFR <30 mL/min/1.73 m²; avoid combining eplerenone/esaxerenone with potassium supplements or potassium‑sparing diuretics; monitor men for gynecomastia with spironolactone; do not discontinue MRA solely because BP and K are well controlled.

Concrete Clinical Example

A 58‑year‑old woman with PA confirmed by AVS, BP 128/76 mmHg on amlodipine 5 mg daily, K 4.2 mmol/L, asks whether she can stop low‑dose spironolactone. She continues MRA; at 4‑week follow‑up K is 4.4 mmol/L, BP stable, no adverse events.

Source: Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021, Japan Endocrine Society, 2021